Literature DB >> 2440556

Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.

A P Sappino, N Busso, D Belin, J D Vassalli.   

Abstract

To assess the postulated correlation between plasminogen activators (PAs) and malignancy, we determined the mRNA content for urokinase-type (u-PA) and tissue-type (t-PA) enzymes in a prospective series of 29 primary lung and 27 primary breast carcinomas. Dot blots of total RNAs were hybridized with appropriate cRNA probes under conditions that allow quantitative measurement of the mRNA level for each PA. Most tumors (43 of 56) had a u-PA mRNA content higher than the mean + 1 SD of nonmalignant tissue counterparts. A large, 4- to 20-fold, increase in u-PA mRNA content was demonstrated in 14 of 29 lung carcinomas and in 10 of 27 breast carcinomas. A statistically significant correlation (Fisher's test, P = 0.007) was found between elevated u-PA mRNA content in lung carcinomas and the presence of regional lymph node metastases. These results are consistent with a role for u-PA in tumor invasiveness and metastatic propensity and may have important prognostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440556

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 3.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

4.  Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.

Authors:  J H Axelrod; R Reich; R Miskin
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

5.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

6.  Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.

Authors:  Z L Gokaslan; S K Chintala; J E York; V Boyapati; S Jasti; R Sawaya; G Fuller; D M Wildrick; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

7.  Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.

Authors:  Izabela Podgorski; Bruce E Linebaugh; Mansoureh Sameni; Christopher Jedeszko; Sunita Bhagat; Michael L Cher; Bonnie F Sloane
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

8.  Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.

Authors:  K Gohji; M Nakajima; D Boyd; C P Dinney; C D Bucana; S Kitazana; S Kamidono; I J Fidler
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

9.  Extracellular proteolysis in the adult murine brain.

Authors:  A P Sappino; R Madani; J Huarte; D Belin; J Z Kiss; A Wohlwend; J D Vassalli
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in paediatric tumour cells. Effects of tumour cell proliferation modulators on gelatinolytic activity.

Authors:  R G de Veas; L Schweigerer; M A Medina
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.